Protara Therapeutics (TARA) Q1 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on cancer and rare diseases, with no approved products or revenue to date.

• Lead programs include TARA-002 for NMIBC and LMs, and IV Choline Chloride for patients on parenteral support.

• Plans to submit a Biologics License Application for TARA-002 in LMs in 2H 2027, following pivotal STARBORN-1 trial results.

• Ongoing engagement with FDA, including transfer of review to Office of Therapeutic Products, experienced in pediatric rare diseases.

• Significant operating losses continue as R&D and G&A expenses rise to support clinical development.

Financial highlights

• Cash, cash equivalents, and investments totaled $177.4 million as of March 31, 2026, expected to fund operations into 2028.

• Net loss of $17.8 million for Q1 2026, compared to $11.9 million in Q1 2025.

• Operating expenses increased to $19.6 million from $14.1 million year-over-year, driven by higher R&D and G&A costs.

• R&D expenses rose by $4.4 million to $13.6 million, mainly due to increased clinical trial activity.

• G&A expenses increased by $1.1 million to $6.1 million, primarily from higher personnel costs.

Outlook and guidance

• Cash position expected to support planned operations and milestones into 2028.

• Plans to complete enrollment in the BCG-unresponsive cohort of the ADVANCED-2 trial for TARA-002 in NMIBC in H2 2026.

• Initiation of ADVANCED-3 trial for TARA-002 in NMIBC expected in H2 2026.

• Interim results from the THRIVE-3 Phase 3 trial for IV Choline Chloride anticipated in H2 2026.

• Biologics License Application for TARA-002 in LMs planned for H2 2027.